January 2, 2018 / 10:24 AM / 20 days ago

BRIEF-Walvax Biotechnology unit gets approval for clinical trail on new drug GB223 injection

Jan 2 (Reuters) - Walvax Biotechnology Co Ltd :

* Says its controlling biotech unit got approval for clinical trail of new drug GB223 injection, which is used for treatment of osteoporosis, bone metastasis of solid tumor and other related diseases

Source text in Chinese: goo.gl/WFpKij

Further company coverage: (Beijing Headline News)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below